It’s not surprising that prostate cancer is the second-leading cause of cancer-related death in men, as most of us know someone affected by the disease. Although recent improvements in diagnosis and therapy have given men some further advantages, alternatives for those with a particular aggressive type of the disease — known as biochemically relapsed prostate cancer (BRPC) — have historically been scarce.
In these patients, hormonal therapies are often employed; however, there are serious hazards involved. Alternative treatment options that do not rely on harmful hormonal pathways have therefore become critical.
A Breakthrough in Prostate Cancer Care — Landmark Study Just Published
A recently published clinical trial on the supplement Modified Citrus Pectin demonstrates tremendous promise for men with BRPC. These results, from the final arm of an 18-month phase II multi-oncology center clinical trial, were originally presented at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium and published online in the Journal of Clinical Oncology in February 2023.
The significance of a dietary supplement being studied in a multi-oncology center clinical trial — not to mention published in a major cancer medical journal — represents a landmark breakthrough in integrative cancer research.
Final results from the long-term clinical trial are equally impressive: The long-term study, which concluded in August 2023, showcased the remarkable benefits of modified citrus pectin (MCP) in combating prostate cancer progression and PSA doubling time (PSADT) in men with BRPC.
The study, published in the esteemed journal Nutrients with an impact factor of 5.7, highlighted MCP’s potential as a nutritional intervention. Over 18 months, researchers monitored 59 patients with BRPC who regularly consumed 4.8 grams of MCP three times a day. The first six-month results, published in October 2021, showed promising outcomes. Of the participants, 78% responded positively to MCP, with 58% experiencing decreased or stabilized PSA levels. Additionally, 75% saw an improvement in PSADT with negative scans.
For the final phase of the trial, 46 subjects continued taking MCP for an additional 12 months. Remarkably, 90% of these individuals showed improvement or stabilization in PSADT, 62% experienced decreased or stable PSA levels, and 85% showed no signs of disease progression in biochemical and scan assessments. Notably, no adverse effects or toxicity were seen throughout the study.
MCP — an Effective Alternative Without Side Effects
This groundbreaking clinical trial is a meaningful achievement as it sheds light on the substantial advantages and safety of MCP — a non-hormonal treatment — in managing aggressive prostate cancer. The findings contribute to the growing body of evidence supporting the potential of MCP in integrative cancer treatment.
Given the limited therapeutic options for this patient population and the risks associated with hormonal interventions in prostate cancer, MCP appears as an effective alternative with fewer complications.
With more 80 published studies and 30+ years of clinical use, MCP has become one of the most extensively researched dietary supplements, showcasing its clinically relevant benefits in various areas of health, including cancer, cardiovascular health, and kidney health. This study further contributes to the growing body of evidence supporting MCP’s potential in oncology and other critical health domains.
You may also like: Dr. Eliaz’s Prostate Wellness Guide.
